{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T23:17:34Z","timestamp":1777936654698,"version":"3.51.4"},"reference-count":19,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T00:00:00Z","timestamp":1388361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Mult Scler"],"published-print":{"date-parts":[[2014,7]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>In a retrospective study, we have previously shown that work ability was improved after the initiation of natalizumab treatment in relapsing\u2013remitting multiple sclerosis (RRMS). In another prospective trial (TYNERGY) the effect on MS-related fatigue was evaluated after 12 months of treatment with natalizumab. A comprehensive Capacity for Work Questionnaire (CWQ) was used to collect data regarding number of working hours and sickness absence. The predefined intention-to-treat analysis regarding work ability did not, however, show significant results.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The objective of this paper is to assess the amount of sick leave in RRMS before and after one year of natalizumab treatment and correlate it to fatigue and walking ability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This is a post-hoc analysis of the complete data from the CWQ used in the TYNERGY trial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>MS patients receiving sickness benefit before start of treatment reduced their sickness benefit by an absolute change of 33% after one year of natalizumab treatment. Younger age and improvement of walking ability correlated significantly with reduction of sick leave.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This ad-hoc analysis of prospectively collected data supported our previous retrospective study and thus indicates a positive relationship between natalizumab treatment and improvement in work ability.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/1352458513517590","type":"journal-article","created":{"date-parts":[[2013,12,30]],"date-time":"2013-12-30T21:03:58Z","timestamp":1388437438000},"page":"1095-1101","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":14,"title":["Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial"],"prefix":"10.1177","volume":"20","author":[{"given":"Anne","family":"Wickstr\u00f6m","sequence":"first","affiliation":[{"name":"Department of Pharmacology and Clinical Neuroscience, Section of Neuroscience, Ume\u00e5 University, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charlotte","family":"Dahle","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Clinical Immunology, Faculty of Health Sciences, Link\u00f6ping University, Sweden"},{"name":"Clinical Immunology and Transfusion Medicine, County Council of \u00d6sterg\u00f6tland, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Vrethem","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, Neurology and Clinical Neurophysiology, Faculty of Health Sciences, Link\u00f6ping University, Sweden"},{"name":"Department of Neurology and Neurophysiology, County Council of \u00d6sterg\u00f6tland, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Svenningsson","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Clinical Neuroscience, Section of Neuroscience, Ume\u00e5 University, Sweden"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2013,12,30]]},"reference":[{"key":"bibr1-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61620-7"},{"key":"bibr2-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1331.2009.02572.x"},{"key":"bibr3-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1191\/1352458503ms955oa"},{"key":"bibr4-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-006-0379-5"},{"key":"bibr5-1352458513517590","unstructured":"Multiple Sclerosis International Federation. MSIF survey on employment and MS. Global survey: Multiple Sclerosis International Federation 2010 April. http:\/\/www.msif.org\/includes\/documents\/cm_docs\/2013\/m\/msif-survey-on-employment-and-ms.pdf?f=1."},{"key":"bibr6-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-13-224"},{"key":"bibr7-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512461391"},{"key":"bibr8-1352458513517590","doi-asserted-by":"publisher","DOI":"10.2165\/11593770-000000000-00000"},{"key":"bibr9-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.7.1.123"},{"key":"bibr10-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa044397"},{"key":"bibr11-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0058643"},{"key":"bibr12-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1177\/1352458509348519"},{"key":"bibr13-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1378\/chest.07-1682"},{"key":"bibr14-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1177\/1352458507082607"},{"key":"bibr15-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1177\/1352458512444498"},{"key":"bibr16-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-0009-2"},{"key":"bibr17-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063172"},{"key":"bibr18-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2005.08.006"},{"key":"bibr19-1352458513517590","doi-asserted-by":"publisher","DOI":"10.1177\/1352458511407951"}],"container-title":["Multiple Sclerosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458513517590","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1352458513517590","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1352458513517590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T03:39:39Z","timestamp":1777693179000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1352458513517590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,30]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["10.1177\/1352458513517590"],"URL":"https:\/\/doi.org\/10.1177\/1352458513517590","relation":{},"ISSN":["1352-4585","1477-0970"],"issn-type":[{"value":"1352-4585","type":"print"},{"value":"1477-0970","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,30]]}}}